Advertisement
Advertisement
U.S. markets open in 5 hours 28 minutes
Advertisement
Advertisement
Advertisement
Advertisement

BioRestorative Therapies, Inc. (BRTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.4731+0.1031 (+3.06%)
At close: 04:00PM EDT
3.5700 +0.10 (+2.79%)
After hours: 06:50PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.3700
Open3.4500
Bid0.0000 x 800
Ask0.0000 x 1200
Day's Range3.4000 - 3.4990
52 Week Range2.7500 - 32.0000
Volume12,159
Avg. Volume20,994
Market Cap12.634M
Beta (5Y Monthly)77.95
PE Ratio (TTM)N/A
EPS (TTM)-17.7440
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BRTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioRestorative Therapies, Inc.
    Analyst Report: Pinterest, Inc.Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
    Rating
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • GlobeNewswire

    BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

    First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the first patient has been enrolled in the Company’s Phase 2 clinical trial evaluating the safety and preliminary efficacy of BRTX-100, an autologous bone marrow-derived mesenchymal stem cell targeting chronic lumbar disc disease (cLDD). T

  • GlobeNewswire

    BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

    MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has reached an agreement with its second clinical site for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Center for Clinical Research, which is located in North Carolina, is BioRestorative’s second clinical trial contract executed. BioRestorative’s Phase

  • Benzinga

    EXCLUSIVE: BioRestorative Selects Second Site For Its Lumbar Disc Disease Study

    BioRestorative Therapies Inc (NASDAQ: BRTX) has selected the Center for Clinical Research in North Carolina as the company's second contract for its Phase 2 trial targeting chronic lumbar disc disease (cLDD). BioRestorative develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. What Happened: The Phase 2 trial will evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the company's autologous investigational stem cell

Advertisement
Advertisement